Janux Therapeutics (JANX) Free Cash Flow: 2020-2025
Historic Free Cash Flow for Janux Therapeutics (JANX) over the last 5 years, with Sep 2025 value amounting to -$12.9 million.
- Janux Therapeutics' Free Cash Flow fell 473.98% to -$12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$71.4 million, marking a year-over-year decrease of 88.77%. This contributed to the annual value of -$44.2 million for FY2024, which is 15.74% up from last year.
- Latest data reveals that Janux Therapeutics reported Free Cash Flow of -$12.9 million as of Q3 2025, which was up 46.68% from -$24.3 million recorded in Q2 2025.
- In the past 5 years, Janux Therapeutics' Free Cash Flow registered a high of $5.4 million during Q1 2021, and its lowest value of -$24.3 million during Q2 2025.
- Over the past 3 years, Janux Therapeutics' median Free Cash Flow value was -$14.3 million (recorded in 2023), while the average stood at -$13.7 million.
- Its Free Cash Flow has fluctuated over the past 5 years, first crashed by 581.60% in 2021, then surged by 81.48% in 2024.
- Over the past 5 years, Janux Therapeutics' Free Cash Flow (Quarterly) stood at -$11.1 million in 2021, then decreased by 25.73% to -$14.0 million in 2022, then grew by 25.43% to -$10.4 million in 2023, then plummeted by 60.97% to -$16.8 million in 2024, then crashed by 473.98% to -$12.9 million in 2025.
- Its last three reported values are -$12.9 million in Q3 2025, -$24.3 million for Q2 2025, and -$17.4 million during Q1 2025.